Sharquie, K.E., Al-Rawi, J.R., Noaimi, A.A. and Majly, W.H. (2016) Tuberculin as Intralesional Therapy for Viral Warts-Single-Blind, Split, Placebo, Controlled Study. Journal of Cosmetics, Dermatological Sciences and Applications, 6, 191-198.
https://doi.org/10.4236/jcdsa.2016.65024

has been cited by the following article:

• TITLE: Managing Recalcitrant Warts: Facts about Bacillus Calmette-Guerin (BCG), Mycobacterium Indicus Pranii (Mw Vaccine), and Purified Protein Derivative (PPD) as Immunotherapy

  AUTHORS: Nabeel K. Al Hamzawi, Mais H. Abdallah

  KEYWORDS: Recalcitrant Warts, BCG Vaccine, Mycobacterium W Vaccine, PPD (Purified Protein Derivative)

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.8 No.4, December 3, 2018

  ABSTRACT: Recalcitrant warts can accurately be defined as warts that persist after six months of conventional therapy. Up to one-third of non-genital warts, especially periungual and plantar warts, become recalcitrant. Traditional treatment options for warts include topical salicylic acid, cryotherapy, and electrocautery; however, patients with recalcitrant warts remain a major therapeutic challenge. There is evidence that immunotherapy can clear recalcitrant warts if traditional treatment fails. Given this, clinical studies published in PubMed and Google Scholar that used Bacillus Calmette-Guerin (BCG), Mycobacterium Indicus Pranii (Mw vaccine), and purified protein derivative (PPD) as immunotherapy for wart, were reviewed in this study. Neither of these treatments has been subjected to a randomized controlled trial, thus to date, there are no standardized protocols to use them. Our review highlights the scientific facts in the clinical applications of the previous options to treat recalcitrant warts and investigate the differences among them, concerning efficacy, adverse effects, dosage, and route of administration.